PharmaMar Presents New Data on Plitidepsin, Lurbinectedin Therapies to Treat Ovarian Cancer, Multiple Myeloma

PharmaMar Presents New Data on Plitidepsin, Lurbinectedin Therapies to Treat Ovarian Cancer, Multiple Myeloma
Plitidepsin and lurbinectedin, two drugs advancing in clinical studies for the treatment of ovarian cancer and other malignancies, were the focus of two PharmaMar presentations at the April 1-5 American Association of Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. The first presentation, “Plitidepsin targets the moonlighting functions of eEF1A2 in cancer,” revealed the exact mechanism of action of plitidepsin, a

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *